• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

SULINDAC Drug Record

  • Summary
  • Interactions
  • Claims
  • SULINDAC chembl:CHEMBL15770 ApprovedAntineoplastic

    Alternate Names:

    CLINORIL
    MK-231
    SULINDAC
    CIS-5-FLUORO-2-METHYL-1-((P-METHYLSULFINYL)BENZYLIDENE)INDENE-3-ACETIC ACID
    CIS-5-FLUORO-2-METHYL-1-((4-(METHYLSULFINYL)PHENYL)METHYLENE)-1H-INDENE-3-ACETIC ACID
    SULINDACUM
    (Z)-5-FLUORO-2-METHYL-1-((P-(METHYLSULFINYL)PHENYL)METHYLENE)-1H-INDENE-3-ACETIC ACID
    SULINDACO
    CLINORIL®
    chembl:CHEMBL15770
    pubchem.compound:1548887
    rxcui:10237
    chemidplus:38194-50-2
    drugbank:00605

    Drug Info:

    Drug Class anti-inflammatory agents, non-steroidal
    Year of Approval 1978
    Drug Categories indenes
    Drug Categories anti-inflammatory agents, non-steroidal
    FDA Approval 1978
    Drug Class small molecule
    Drug Indications NSAID
    Drug Groups investigational
    Drug Categories agents causing hyperkalemia
    Drug Categories agents that produce hypertension
    Drug Categories anti-inflammatory agents, non-steroidal (non-selective)
    Drug Categories drugs causing inadvertant photosensitivity
    Drug Categories nephrotoxic agents
    Drug Categories non cox-2 selective nsaids
    Drug Categories oat1/slc22a6 inhibitors
    Drug Categories other nonsteroidal anti-inflammatory agents
    Drug Categories photosensitizing agents
    (8 More Sources)

    Publications:

    Taylor et al., 2000, Sulindac sulfone inhibits K-ras-dependent cyclooxygenase-2 expression in human colon cancer cells., Cancer Res.
    Giuliano et al., 1999, Ex vivo assay to determine the cyclooxygenase selectivity of non-steroidal anti-inflammatory drugs., Br. J. Pharmacol.
    Yip-Schneider et al., 2000, Cyclooxygenase-2 expression in human pancreatic adenocarcinomas., Carcinogenesis
    Molina et al., 1999, Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs., Cancer Res.
    Fosslien, 2000, Biochemistry of cyclooxygenase (COX)-2 inhibitors and molecular pathology of COX-2 in neoplasia., Crit Rev Clin Lab Sci
    Itano et al., 2009, Sulindac effects on inflammation and tumorigenesis in the intestine of mice with Apc and Mlh1 mutations., Carcinogenesis
    Koornstra et al., 2005, Sulindac inhibits beta-catenin expression in normal-appearing colon of hereditary nonpolyposis colorectal cancer and familial adenomatous polyposis patients., Cancer Epidemiol. Biomarkers Prev.
    Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
    Cheng et al., 2002, Vascular effects of COX inhibition and AT1 receptor blockade in transgenic rats harboring mouse renin-2 gene., J. Physiol. Pharmacol.
    Soriano et al., 1999, Synergistic effects of new chemopreventive agents and conventional cytotoxic agents against human lung cancer cell lines., Cancer Res.
    Cheng et al., 2003, Cardiovascular and renal effects of cyclooxygenase inhibition in transgenic rats harboring mouse renin-2 gene (TGR[mREN2]27)., Eur. J. Pharmacol.
    Lim et al., 1999, Sulindac derivatives inhibit growth and induce apoptosis in human prostate cancer cell lines., Biochem. Pharmacol.
    Wang ZG et al., 2013, Synthesis and SAR study of modulators inhibiting tRXRα-dependent AKT activation., Eur J Med Chem
    Ferner et al., 1991, The effects of enalapril and sulindac on the dermal response to substance P and neurokinin A., Br J Clin Pharmacol
    van der Sloot et al., 1995, Sulindac in established experimental diabetes: a follow-up study., Can J Neurol Sci
    Chaudhry et al., 1983, Inhibition of human lens aldose reductase by flavonoids, sulindac and indomethacin., Biochem. Pharmacol.
    Sharma et al., Topical sulindac therapy in diabetic senile cataracts: cataract-IV., Indian J Ophthalmol
    Jacobson et al., 1983, Diabetic complications in lens and nerve and their prevention by sulindac or sorbinil: two novel aldose reductase inhibitors., Invest. Ophthalmol. Vis. Sci.
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Crabbe et al., 1985, The inhibition of bovine lens aldose reductase by Clinoril, its absorption into the human red cell and its effect on human red cell aldose reductase activity., Ophthalmic Res.
    Kim et al., 2006, Inhibition of chemically induced skin carcinogenesis by sulindac is independent of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta)., Carcinogenesis
    Babbar et al., 2003, Cyclooxygenase-independent induction of apoptosis by sulindac sulfone is mediated by polyamines in colon cancer., J. Biol. Chem.
    Liou et al., 2007, Nonsteroidal anti-inflammatory drugs induce colorectal cancer cell apoptosis by suppressing 14-3-3epsilon., Cancer Res.
    Jarvis et al., 2005, Both PPARgamma and PPARdelta influence sulindac sulfide-mediated p21WAF1/CIP1 upregulation in a human prostate epithelial cell line., Oncogene
    He et al., 1999, PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs., Cell
    Hedberg ML et al., 2019, Use of nonsteroidal anti-inflammatory drugs predicts improved patient survival for <i>PIK3CA</i>-altered head and neck cancer., J Exp Med
    Yip-Schneider et al., Inhibition of the phosphatidylinositol 3'-kinase signaling pathway increases the responsiveness of pancreatic carcinoma cells to sulindac., J. Gastrointest. Surg.
    Pyrko et al., 2006, Downregulation of survivin expression and concomitant induction of apoptosis by celecoxib and its non-cyclooxygenase-2-inhibitory analog, dimethyl-celecoxib (DMC), in tumor cells in vitro and in vivo., Mol. Cancer
    Jin et al., 2006, Synergistic induction of apoptosis by sulindac and arsenic trioxide in human lung cancer A549 cells via reactive oxygen species-dependent down-regulation of survivin., Biochem. Pharmacol.
    Hata et al., 2005, Structural determinants of arylacetic acid nonsteroidal anti-inflammatory drugs necessary for binding and activation of the prostaglandin D2 receptor CRTH2., Mol. Pharmacol.
    Rice et al., 2004, Inhibition of extracellular-signal regulated kinases 1/2 is required for apoptosis of human colon cancer cells in vitro by sulindac metabolites., Cancer Res.
    Rice et al., 2006, Sulindac independently modulates extracellular signal-regulated kinase 1/2 and cyclic GMP-dependent protein kinase signaling pathways., Mol. Cancer Ther.
    Rice et al., 2001, Inhibition of extracellular signal-regulated kinase 1/2 phosphorylation and induction of apoptosis by sulindac metabolites., Cancer Res.
    Rice et al., 2003, Sulindac sulfide inhibits epidermal growth factor-induced phosphorylation of extracellular-regulated kinase 1/2 and Bad in human colon cancer cells., Cancer Res.
    Pangburn et al., 2005, Sulindac metabolites inhibit epidermal growth factor receptor activation and expression., J Carcinog
    Wilson et al., 2002, Novel detection and differential utilization of a c-myc transcriptional block in colon cancer chemoprevention., Cancer Res.
    Cousido-Siah A et al., 2015, Structural analysis of sulindac as an inhibitor of aldose reductase and AKR1B10., Chem Biol Interact
  • SULINDAC   TNFRSF10A

    Interaction Score: 1.29

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16030090


    Sources:
    NCI

  • SULINDAC   AKR1B1

    Interaction Score: 0.71

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    8529171 6409111 2632448 6413448 11752352 3920599


    Sources:
    TTD DrugBank

  • SULINDAC   AKR1B10

    Interaction Score: 0.57

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    25532697


    Sources:
    DrugBank

  • SULINDAC   MAPK3

    Interaction Score: 0.34

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    15548677 16546990 11245463 12566304 16138927


    Sources:
    DrugBank

  • SULINDAC   FMO3

    Interaction Score: 0.32

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • SULINDAC   APC

    Interaction Score: 0.27

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Evidence Type Actionable
    Approval Status Preclinical
    Response Type sensitive

    PMIDs:
    19755659


    Sources:
    JAX-CKB

  • SULINDAC   PTGS1

    Interaction Score: 0.23

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction? False
    Endogenous Drug? False
    Specific Action of the Ligand Inhibition

    PMIDs:
    10372826 12512695 10626810 12586211 10484067


    Sources:
    TEND TdgClinicalTrial DrugBank GuideToPharmacology ChemblInteractions

  • SULINDAC   TAC1

    Interaction Score: 0.23

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    1707646


    Sources:
    NCI

  • SULINDAC   PTGDR2

    Interaction Score: 0.22

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:

    PMIDs:
    15563582


    Sources:
    DrugBank

  • SULINDAC   PTGS2

    Interaction Score: 0.21

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name -
    Novel drug target Established target
    Mechanism of Interaction Cyclooxygenase inhibitor

    PMIDs:
    11118042 10372826 10657949 10485483 11078056


    Sources:
    TEND TdgClinicalTrial DrugBank GuideToPharmacology ChemblInteractions

  • SULINDAC   BIRC5

    Interaction Score: 0.2

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16707021 16950207


    Sources:
    NCI

  • SULINDAC   MYC

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12414619


    Sources:
    NCI

  • SULINDAC   PPARD

    Interaction Score: 0.11

    Interaction Types & Directionality:
    negative modulator (inhibitory)

    Interaction Info:

    PMIDs:
    16418176 14506281 17409426 16091736 10555149


    Sources:
    DrugBank

  • SULINDAC   RXRA

    Interaction Score: 0.09

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Direct Interaction? False
    Endogenous Drug? False
    Specific Action of the Ligand Antagonist

    PMIDs:
    23434637


    Sources:
    DTC GuideToPharmacology

  • SULINDAC   PIK3CA

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    30683736 12654560


    Sources:
    NCI CIViC

  • SULINDAC   CYP2C9

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • SULINDAC   CYP2C19

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • SULINDAC   KDM4E

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • SULINDAC   CYP1A2

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • SULINDAC   CYP2D6

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • SULINDAC   CYP3A4

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • SULINDAC   EHMT2

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DrugBank: DB00605

    • Version: 5.1.7

    Alternate Names:
    SULINDAC DrugBank Drug Name
    38194-50-2 CAS Number
    Apo-sulin Tab 150mg Drug Brand

    Drug Info:
    Drug Type small molecule
    Drug Groups approved
    Drug Groups investigational

    Publications:
    Giuliano et al., 1999, Ex vivo assay to determine the cyclooxygenase selectivity of non-steroidal anti-inflammatory drugs., Br. J. Pharmacol.
    Cheng et al., 2002, Vascular effects of COX inhibition and AT1 receptor blockade in transgenic rats harboring mouse renin-2 gene., J. Physiol. Pharmacol.
    Soriano et al., 1999, Synergistic effects of new chemopreventive agents and conventional cytotoxic agents against human lung cancer cell lines., Cancer Res.

  • TEND: SULINDAC

    • Version: 01-August-2011

    Alternate Names:
    SULINDAC Primary Drug Name

    Drug Info:
    Year of Approval 1978
    Drug Class anti-inflammatory agents, non-steroidal

    Publications:

  • TdgClinicalTrial: SULINDAC

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications NSAID
    Drug Class small molecule
    FDA Approval 1978

    Publications:

  • NCI: SULINDAC

    • Version: 14-September-2017

    Alternate Names:
    C850 NCI drug code

    Drug Info:

    Publications:
    Pyrko et al., 2006, Downregulation of survivin expression and concomitant induction of apoptosis by celecoxib and its non-cyclooxygenase-2-inhibitory analog, dimethyl-celecoxib (DMC), in tumor cells in vitro and in vivo., Mol. Cancer
    Jin et al., 2006, Synergistic induction of apoptosis by sulindac and arsenic trioxide in human lung cancer A549 cells via reactive oxygen species-dependent down-regulation of survivin., Biochem. Pharmacol.
    Wilson et al., 2002, Novel detection and differential utilization of a c-myc transcriptional block in colon cancer chemoprevention., Cancer Res.

  • DTC: SULINDAC

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL15770 ChEMBL Drug ID

    Drug Info:

    Publications:
    Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
    Wang ZG et al., 2013, Synthesis and SAR study of modulators inhibiting tRXRα-dependent AKT activation., Eur J Med Chem

  • JAX-CKB: Sulindac

    • Version: 27-September-2017

    Alternate Names:

    Drug Info:

    Publications:
    Itano et al., 2009, Sulindac effects on inflammation and tumorigenesis in the intestine of mice with Apc and Mlh1 mutations., Carcinogenesis

  • CIViC: SULINDAC

    • Version: 14-September-2020

    Alternate Names:

    Drug Info:

    Publications:
    Hedberg ML et al., 2019, Use of nonsteroidal anti-inflammatory drugs predicts improved patient survival for <i>PIK3CA</i>-altered head and neck cancer., J Exp Med

  • TTD: Sulindac

    • Version: 2020.06.01

    Alternate Names:
    D0Z5IU TTD Drug ID

    Drug Info:

    Publications:

  • GuideToPharmacology: 178102078

    • Version: 29-September-2020

    Alternate Names:
    SULINDAC GuideToPharmacology Ligand Name

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL15770

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL15770

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • PharmGKB: sulindac

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21